JAMA
Social media drug ads draw high engagement—but raise oversight concerns
A JAMA research letter analyzed top-performing social media posts promoting GLP-1 agonists, ADHD stimulants, and autoimmune biologics, finding frequent omission of FDA-required risk information. Posts often blurred lines between personal testimonials and marketing, amplified by platform algorithms.
Clinical takeaway: Clinicians should counsel patients that highly engaging drug-related content on social media may lack balanced safety details and shouldn’t replace evidence-based guidance.
Source:
Kresovich A, et al. (2025, November 13). JAMA. High-Engagement Social Media Posts Related to Prescription Drug Promotion for 3 Major Drug Classes. https://pubmed.ncbi.nlm.nih.gov/41231482/